Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Next Previous
X
Search
Trial Profile

A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pacritinib (Primary) ; Ruxolitinib
  • Indications Myelofibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSIST-2
  • Sponsors Cell Therapeutics; CTI BioPharma

    • Most Recent Events

    • 04 Jun 2024 Results representing data on spleen and symptom benefit in PAC-treated pts with moderate or severe bicytopenia. presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2024 Results evaluating the impact of PAC versus best available therapy (BAT), including ruxolitinib (RUX), on symptom burden in patients with baseline RBC transfusions presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2023 Results (n=41) evaluating relationship between transfusion independence and reduction in BMF in MF patients treated with pacritinib, presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top